Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-30

Clinical Trial Update: Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy [Phase 4]

View source ↗

Summary

Phase 4 rollover study of sacituzumab govitecan-hziy in participants with metastatic solid tumors; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan-hziy)

Snippet

Sponsor: Gilead Sciences | Conditions: Metastatic Solid Tumors | Phase 4 | Status: COMPLETED | Results posted: 2025-09-30